Cargando…

Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus

Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Papaneophytou, Christos, Nicolaou, Andria, Pieri, Myrtani, Nicolaidou, Vicky, Galatou, Eleftheria, Sarigiannis, Yiannis, Pantelidou, Markella, Panayi, Pavlos, Thoma, Theklios, Stavraki, Antonia, Argyrou, Xenia, Kalogiannis, Tasos, Yiannoukas, Kyriacos, Petrou, Christos C., Felekkis, Kyriacos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191710/
https://www.ncbi.nlm.nih.gov/pubmed/35696396
http://dx.doi.org/10.1371/journal.pone.0269885
_version_ 1784726075236941824
author Papaneophytou, Christos
Nicolaou, Andria
Pieri, Myrtani
Nicolaidou, Vicky
Galatou, Eleftheria
Sarigiannis, Yiannis
Pantelidou, Markella
Panayi, Pavlos
Thoma, Theklios
Stavraki, Antonia
Argyrou, Xenia
Kalogiannis, Tasos
Yiannoukas, Kyriacos
Petrou, Christos C.
Felekkis, Kyriacos
author_facet Papaneophytou, Christos
Nicolaou, Andria
Pieri, Myrtani
Nicolaidou, Vicky
Galatou, Eleftheria
Sarigiannis, Yiannis
Pantelidou, Markella
Panayi, Pavlos
Thoma, Theklios
Stavraki, Antonia
Argyrou, Xenia
Kalogiannis, Tasos
Yiannoukas, Kyriacos
Petrou, Christos C.
Felekkis, Kyriacos
author_sort Papaneophytou, Christos
collection PubMed
description Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein were higher in individuals with evidence of prior infection who received at least one dose of either an mRNA-based vaccine (Comirnaty BNT162b2/Pfizer-BioNTech or Spikevax mRNA-1273/Moderna) or an adenoviral-based vaccine (Vaxzervia ChAdOx1 nCoV-19 /Oxford-Astra Zeneca) (n = 39) compared to i) unvaccinated individuals with evidence of prior infection with SARS-CoV-2 (n = 109) and ii) individuals without evidence of prior infection with SARS-CoV-2 who received one or two doses of one of the aforementioned vaccines (n = 342). Our analysis also revealed that regardless of the vaccine technology (mRNA-based and adenoviral vector-based) two doses achieved high anti- SARS-CoV-2 IgG responses. Our results indicate that vaccine-induced responses lead to higher levels of IgG antibodies compared to those produced following infection with the virus. Additionally, in agreement with previous studies, our results suggest that among individuals previously infected with SARS-CoV-2, even a single dose of a vaccine is adequate to elicit high levels of antibody response.
format Online
Article
Text
id pubmed-9191710
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91917102022-06-14 Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus Papaneophytou, Christos Nicolaou, Andria Pieri, Myrtani Nicolaidou, Vicky Galatou, Eleftheria Sarigiannis, Yiannis Pantelidou, Markella Panayi, Pavlos Thoma, Theklios Stavraki, Antonia Argyrou, Xenia Kalogiannis, Tasos Yiannoukas, Kyriacos Petrou, Christos C. Felekkis, Kyriacos PLoS One Research Article Monitoring the levels of IgG antibodies against the SARS-CoV-2 is important during the coronavirus disease 2019 (COVID-19) pandemic, to plan an adequate and evidence-based public health response. After this study we report that the plasma levels of IgG antibodies against SARS-CoV-2 spike protein were higher in individuals with evidence of prior infection who received at least one dose of either an mRNA-based vaccine (Comirnaty BNT162b2/Pfizer-BioNTech or Spikevax mRNA-1273/Moderna) or an adenoviral-based vaccine (Vaxzervia ChAdOx1 nCoV-19 /Oxford-Astra Zeneca) (n = 39) compared to i) unvaccinated individuals with evidence of prior infection with SARS-CoV-2 (n = 109) and ii) individuals without evidence of prior infection with SARS-CoV-2 who received one or two doses of one of the aforementioned vaccines (n = 342). Our analysis also revealed that regardless of the vaccine technology (mRNA-based and adenoviral vector-based) two doses achieved high anti- SARS-CoV-2 IgG responses. Our results indicate that vaccine-induced responses lead to higher levels of IgG antibodies compared to those produced following infection with the virus. Additionally, in agreement with previous studies, our results suggest that among individuals previously infected with SARS-CoV-2, even a single dose of a vaccine is adequate to elicit high levels of antibody response. Public Library of Science 2022-06-13 /pmc/articles/PMC9191710/ /pubmed/35696396 http://dx.doi.org/10.1371/journal.pone.0269885 Text en © 2022 Papaneophytou et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Papaneophytou, Christos
Nicolaou, Andria
Pieri, Myrtani
Nicolaidou, Vicky
Galatou, Eleftheria
Sarigiannis, Yiannis
Pantelidou, Markella
Panayi, Pavlos
Thoma, Theklios
Stavraki, Antonia
Argyrou, Xenia
Kalogiannis, Tasos
Yiannoukas, Kyriacos
Petrou, Christos C.
Felekkis, Kyriacos
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
title Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
title_full Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
title_fullStr Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
title_full_unstemmed Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
title_short Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
title_sort seroprevalence of immunoglobulin g antibodies against sars-cov-2 in cyprus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191710/
https://www.ncbi.nlm.nih.gov/pubmed/35696396
http://dx.doi.org/10.1371/journal.pone.0269885
work_keys_str_mv AT papaneophytouchristos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT nicolaouandria seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT pierimyrtani seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT nicolaidouvicky seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT galatoueleftheria seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT sarigiannisyiannis seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT pantelidoumarkella seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT panayipavlos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT thomatheklios seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT stavrakiantonia seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT argyrouxenia seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT kalogiannistasos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT yiannoukaskyriacos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT petrouchristosc seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus
AT felekkiskyriacos seroprevalenceofimmunoglobulingantibodiesagainstsarscov2incyprus